Skip to main content
. 2023 Jun 22;6(6):e1349. doi: 10.1002/hsr2.1349

Figure 1.

Figure 1

Schematic of a patient pathway in lung cancer outlining the barriers to implementing diagnostic biomarker testing at each stage of the pathway for the different stakeholder groups: HCPs, patients, diagnostic labs, and payers. COVID‐19, coronavirus disease 2019; HCP, healthcare professional.